Mizuho Securities analyst Steven Valiquette has maintained their bullish stance on COR stock, giving a Buy rating on February 6.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Steven Valiquette has given his Buy rating due to a combination of factors surrounding Cencora’s performance and outlook. Firstly, the company has demonstrated strong revenue growth in its U.S. Healthcare Solutions segment, with an increase from previous guidance, despite the anticipated deceleration in growth due to specific customer changes. The acquisition of new customers like Meijer, which compensates for the loss of Publix, reflects positively on the company’s ability to maintain its revenue streams.
Additionally, Cencora’s management has downplayed the impact of any potential slowdown in GLP-1 drug sales on their earnings, highlighting the low-margin nature of these products. Furthermore, the strategic relationship with Walgreens is expected to remain stable, with future contract revisions likely having minimal impact on Cencora’s earnings per share. Considering these factors, alongside strong earnings results from the first fiscal quarter of 2025, Valiquette maintains a positive outlook for Cencora, reflected in a stable price target of $280.
In another report released on February 6, Evercore ISI also maintained a Buy rating on the stock with a $280.00 price target.